Truvada

This page features: Cited Research Articles The US Department of Health and Human Services (HHS), and pharmaceutical company Gilead Sciences Inc. continue to wage war over government-owned patents for HIV pre-exposure prophylaxis (PrEP), or drugs to help prevent uninfected patients from contracting the virus.  In this case, the US Patent Trial and Appeal Board on Feb. …

US government, drugmaker Gilead come to a head over patents for HIV antiviral Truvada Read More »

This page features: Cited Research Articles Gilead Sciences Inc. was hit with another lawsuit on January 15, 2020, in Miami Federal Court. The company along with Johnson & Johnson, Japan Tobacco Inc., and Bristol-Myers Squibb Co. were sued because of claims of an HIV prevention therapies drug market conspiracy.  The suit states that Gilead extended patent …

All about the money for Truvada, what’s the benefit to consumers? Read More »

This page features: Cited Research Articles For several years Gilead Sciences have faced allegations of intentionally suppressing better, safer HIV drugs in order to increase profits off of current medications already developed. In 2019, a federal judge motioned for a lawsuit filed by claimants in 31 states to proceed. In the lawsuit, plaintiffs allege that Gilead …

Lawsuit alleges HIV drug maker Gilead delayed release of better HIV drugs Read More »

This page features: Cited Research Articles A recent study in Clinical Infectious diseases suggested that patients between the ages of 15 and 19 years of age taking PrEP for HIV prevention, may not recover from bone mineral density loss.  Of particular concern, is that the damage was incurred in the lumbar spine region and whole body …

Total Body Bone Loss Reported In A Single Arm Adolescent Study on Truvada Read More »